BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 35409154)

  • 41. Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235.
    Hall CP; Reynolds CP; Kang MH
    Clin Cancer Res; 2016 Feb; 22(3):621-32. PubMed ID: 26080839
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Beating the Clock in T-cell Acute Lymphoblastic Leukemia.
    Carroll WL; Aifantis I; Raetz E
    Clin Cancer Res; 2017 Feb; 23(4):873-875. PubMed ID: 28007775
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: a retrospective analysis.
    Conter V; Valsecchi MG; Buldini B; Parasole R; Locatelli F; Colombini A; Rizzari C; Putti MC; Barisone E; Lo Nigro L; Santoro N; Ziino O; Pession A; Testi AM; Micalizzi C; Casale F; Pierani P; Cesaro S; Cellini M; Silvestri D; Cazzaniga G; Biondi A; Basso G
    Lancet Haematol; 2016 Feb; 3(2):e80-6. PubMed ID: 26853647
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Childhood acute lymphoblastic leukemia: prognostic value of initial peripheral blast count in good responders to prednisone.
    Felice MS; Zubizarreta PA; Alfaro EM; Sackmann-Muriel F
    J Pediatr Hematol Oncol; 2001 Oct; 23(7):411-5. PubMed ID: 11878573
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Therapeutic strategies for childhood high-risk acute lymphoblastic leukemia].
    Lu XT
    Beijing Da Xue Xue Bao Yi Xue Ban; 2013 Apr; 45(2):327-32. PubMed ID: 23591360
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia.
    Suryani S; Bracken LS; Harvey RC; Sia KC; Carol H; Chen IM; Evans K; Dietrich PA; Roberts KG; Kurmasheva RT; Billups CA; Mullighan CG; Willman CL; Loh ML; Hunger SP; Houghton PJ; Smith MA; Lock RB
    Mol Cancer Ther; 2015 Feb; 14(2):364-74. PubMed ID: 25504635
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia.
    Evangelisti C; Cappellini A; Oliveira M; Fragoso R; Barata JT; Bertaina A; Locatelli F; Simioni C; Neri LM; Chiarini F; Lonetti A; Buontempo F; Orsini E; Pession A; Manzoli L; Martelli AM; Evangelisti C
    J Cell Physiol; 2018 Mar; 233(3):1796-1811. PubMed ID: 28777460
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Inhibition of the Sec61 translocon overcomes cytokine-induced glucocorticoid resistance in T-cell acute lymphoblastic leukaemia.
    Meyer LK; Delgado-Martin C; Sharp PP; Huang BJ; McMinn D; Vincent TL; Ryan T; Horton TM; Wood BL; Teachey DT; Taunton J; Kirk CJ; Hermiston ML
    Br J Haematol; 2022 Jul; 198(1):137-141. PubMed ID: 35434798
    [TBL] [Abstract][Full Text] [Related]  

  • 49. IL-7R is essential for leukemia-initiating cell activity of T-cell acute lymphoblastic leukemia.
    González-García S; Mosquera M; Fuentes P; Palumbo T; Escudero A; Pérez-Martínez A; Ramírez M; Corcoran AE; Toribio ML
    Blood; 2019 Dec; 134(24):2171-2182. PubMed ID: 31530562
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CRLF2 rearrangement in Ph-like acute lymphoblastic leukemia predicts relative glucocorticoid resistance that is overcome with MEK or Akt inhibition.
    Meyer LK; Delgado-Martin C; Maude SL; Shannon KM; Teachey DT; Hermiston ML
    PLoS One; 2019; 14(7):e0220026. PubMed ID: 31318944
    [TBL] [Abstract][Full Text] [Related]  

  • 51. MiR-124 contributes to glucocorticoid resistance in acute lymphoblastic leukemia by promoting proliferation, inhibiting apoptosis and targeting the glucocorticoid receptor.
    Liang YN; Tang YL; Ke ZY; Chen YQ; Luo XQ; Zhang H; Huang LB
    J Steroid Biochem Mol Biol; 2017 Sep; 172():62-68. PubMed ID: 28578002
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Concept and interim result of the ALL-BFM 90 therapy study in treatment of acute lymphoblastic leukemia in children and adolescents: the significance of initial therapy response in blood and bone marrow].
    Schrappe M; Reiter A; Sauter S; Ludwig WD; Wörmann B; Harbott J; Bender-Götze C; Dörffel W; Dopfer R; Frey E
    Klin Padiatr; 1994; 206(4):208-21. PubMed ID: 7526027
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphocytic leukemia.
    Jones B; Freeman AI; Shuster JJ; Jacquillat C; Weil M; Pochedly C; Sinks L; Chevalier L; Maurer HM; Koch K
    Med Pediatr Oncol; 1991; 19(4):269-75. PubMed ID: 2056971
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Single nucleotide polymorphisms in non-coding region of the glucocorticoid receptor gene and prednisone response in childhood acute lymphoblastic leukemia.
    Xue L; Li C; Wang Y; Sun W; Ma C; He Y; Yu Y; Cai L; Wang L
    Leuk Lymphoma; 2015 Jun; 56(6):1704-9. PubMed ID: 25644744
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of glucocorticoid therapy on energy intake in children treated for acute lymphoblastic leukemia.
    Reilly JJ; Brougham M; Montgomery C; Richardson F; Kelly A; Gibson BE
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3742-5. PubMed ID: 11502805
    [TBL] [Abstract][Full Text] [Related]  

  • 56. IL-7 receptor expression is frequent in T-cell acute lymphoblastic leukemia and predicts sensitivity to JAK inhibition.
    Courtois L; Cabannes-Hamy A; Kim R; Delecourt M; Pinton A; Charbonnier G; Feroul M; Smith C; Tueur G; Pivert C; Balducci E; Simonin M; Angel LH; Spicuglia S; Boissel N; Andrieu GP; Asnafi V; Rousselot P; Lhermitte L
    Blood; 2023 Jul; 142(2):158-171. PubMed ID: 37023368
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Initial leukemic gene expression profiles of patients with poor in vivo prednisone response are similar to those of blasts persisting under prednisone treatment in childhood acute lymphoblastic leukemia.
    Cario G; Fetz A; Bretscher C; Möricke A; Schrauder A; Stanulla M; Schrappe M
    Ann Hematol; 2008 Sep; 87(9):709-16. PubMed ID: 18521602
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance.
    Bonapace L; Bornhauser BC; Schmitz M; Cario G; Ziegler U; Niggli FK; Schäfer BW; Schrappe M; Stanulla M; Bourquin JP
    J Clin Invest; 2010 Apr; 120(4):1310-23. PubMed ID: 20200450
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical features, early treatment responses, and outcomes of pediatric acute lymphoblastic leukemia in China with or without specific fusion transcripts: a single institutional study of 1,004 patients.
    Gao C; Zhao XX; Li WJ; Cui L; Zhao W; Liu SG; Yue ZX; Jiao Y; Wu MY; Li ZG
    Am J Hematol; 2012 Nov; 87(11):1022-7. PubMed ID: 22911440
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Concurrent treatment of steroid-related mood and psychotic symptoms with risperidone.
    Ularntinon S; Tzuang D; Dahl G; Shaw RJ
    Pediatrics; 2010 May; 125(5):e1241-5. PubMed ID: 20385646
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.